Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Tipo de documento
Intervalo de ano de publicação
1.
Br J Pharmacol ; 174(16): 2662-2681, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28677901

RESUMO

BACKGROUND AND PURPOSE: Our initial aim was to generate cannabinoid agents that control spasticity, occurring as a consequence of multiple sclerosis (MS), whilst avoiding the sedative side effects associated with cannabis. VSN16R was synthesized as an anandamide (endocannabinoid) analogue in an anti-metabolite approach to identify drugs that target spasticity. EXPERIMENTAL APPROACH: Following the initial chemistry, a variety of biochemical, pharmacological and electrophysiological approaches, using isolated cells, tissue-based assays and in vivo animal models, were used to demonstrate the activity, efficacy, pharmacokinetics and mechanism of action of VSN16R. Toxicological and safety studies were performed in animals and humans. KEY RESULTS: VSN16R had nanomolar activity in tissue-based, functional assays and dose-dependently inhibited spasticity in a mouse experimental encephalomyelitis model of MS. This effect occurred with over 1000-fold therapeutic window, without affecting normal muscle tone. Efficacy was achieved at plasma levels that are feasible and safe in humans. VSN16R did not bind to known CB1 /CB2 /GPPR55 cannabinoid-related receptors in receptor-based assays but acted on a vascular cannabinoid target. This was identified as the major neuronal form of the big conductance, calcium-activated potassium (BKCa ) channel. Drug-induced opening of neuronal BKCa channels induced membrane hyperpolarization, limiting excessive neural-excitability and controlling spasticity. CONCLUSIONS AND IMPLICATIONS: We identified the neuronal form of the BKCa channel as the target for VSN16R and demonstrated that its activation alleviates neuronal excitability and spasticity in an experimental model of MS, revealing a novel mechanism to control spasticity. VSN16R is a potential, safe and selective ligand for controlling neural hyper-excitability in spasticity.


Assuntos
Benzamidas/uso terapêutico , Encefalomielite Autoimune Experimental/tratamento farmacológico , Canais de Potássio Ativados por Cálcio de Condutância Alta/fisiologia , Espasticidade Muscular/tratamento farmacológico , Animais , Benzamidas/química , Benzamidas/farmacocinética , Benzamidas/farmacologia , Cães , Método Duplo-Cego , Endocanabinoides/química , Endocanabinoides/farmacocinética , Endocanabinoides/farmacologia , Endocanabinoides/uso terapêutico , Feminino , Hepatócitos/metabolismo , Isomerismo , Macaca , Masculino , Artérias Mesentéricas/efeitos dos fármacos , Artérias Mesentéricas/fisiologia , Camundongos , Camundongos Knockout , Coelhos , Ratos Sprague-Dawley , Ratos Wistar , Receptor CB1 de Canabinoide/genética , Receptores de Canabinoides/genética , Ducto Deferente/efeitos dos fármacos , Ducto Deferente/fisiologia
2.
Drug Des Devel Ther ; 7: 747-52, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23976843

RESUMO

N-Palmitoylethanolamine (NAE 16:0) is an endogenous lipid signaling molecule that has limited water solubility, and its action is short-lived due to its rapid metabolism. This poses a problem for use in vivo as oral administration requires a high concentration for significant levels to reach target tissues, and injection of the compound in a dimethyl sulfoxide- or ethanol-based vehicle is usually not desirable during long-term treatment. A depot injection of NAE 16:0 was successfully emulsified in sterile corn oil (10 mg/kg) and administered in young DBA/2 mice in order to elevate baseline levels of NAE 16:0 in target tissues. NAE 16:0 levels were increased in various tissues, particularly in the retina, 24 and 48 hours following injections. Increases ranged between 22% and 215% (above basal levels) in blood serum, heart, brain, and retina and induced an entourage effect by increasing levels of other 18 carbon N-Acylethanolamines (NAEs), which ranged between 31% and 117% above baseline. These results indicate that NAE 16:0 can be used as a depot preparation, avoiding the use of inadequate vehicles, and can provide the basis for designing tissue-specific dosing regimens for therapies involving NAEs and related compounds.


Assuntos
Anti-Inflamatórios não Esteroides/farmacocinética , Endocanabinoides/farmacocinética , Etanolaminas/farmacocinética , Ácidos Palmíticos/farmacocinética , Amidas , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Encéfalo/metabolismo , Óleo de Milho/química , Preparações de Ação Retardada , Endocanabinoides/administração & dosagem , Etanolaminas/administração & dosagem , Etanolaminas/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos DBA , Ácidos Palmíticos/administração & dosagem , Veículos Farmacêuticos/química , Retina/metabolismo , Solubilidade , Fatores de Tempo , Distribuição Tecidual
3.
Psiquiatr. biol. (Internet) ; 19(supl.1): 49-58, dic. 2012. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-143533

RESUMO

Los estudios epidemiológicos efectuados en la población general han demostrado sistemáticamente que el consumo de Cannabis aumenta de modo dependiente de la dosis el riesgo de desarrollar trastornos psicóticos. Aunque los indicios epidemiológicos entre el consumo de Cannabis y las psicosis han obtenido una atención considerable, apenas se conoce el mecanismo biológico mediante el que esta droga aumenta el riesgo de psicosis. La investigación en estudios efectuados en animales sugiere que el delta- 9-tetrahidrocanabinol (THC, el componente psicoactivo principal del Cannabis) aumenta los niveles de dopamina en diversas regiones del cerebro, incluido el núcleo estriado y el área prefrontal. Dado que se ha formulado la hipótesis de que la dopamina representa una vía final común decisiva entre la biología del cerebro y la experiencia real de psicosis, inicialmente prestar atención a este neurotransmisor podría ser productivo en el examen de los efectos psicotomiméticos del Cannabis. Por consiguiente, en la presente revisión se examinan las pruebas concernientes a las interacciones entre el THC, los endocanabinoides y la dopamina en la región tanto cortical como subcortical implicadas en las psicosis, y se consideran los posibles mecanismos por los que una disregulación de la dopamina inducida por el consumo de Cannabis podría dar lugar a delirios y alucinaciones. Se concluye que podrían emprenderse productivamente estudios adicionales sobre los mecanismos subyacentes que relacionan el consumo de Cannabis y las psicosis desde una perspectiva de una sensibilización progresiva del desarrollo, como consecuencia de interacciones genes-ambiente (AU)


General population epidemiological studies have consistently found that cannabis use increases the risk of developing psychotic disorders in a dose-dependent manner. While the epidemiological signal between cannabis and psychosis has gained considerable attention, the biological mechanism whereby cannabis increases risk for psychosis remains poorly understood. Animal research suggests that delta-9- tetrahydrocannabinol (THC, the main psychoactive component of cannabis) increases dopamine levels in several regions of the brain, including striatal and prefrontal areas. Since dopamine is hypothesized to represent a crucial common final pathway between brain biology and actual experience of psychosis, a focus on dopamine may initially be productive in the examination of the psychotomimetic effects of cannabis. Therefore, this review examines the evidence concerning the interactions between THC, endocannabinoids and dopamine in the cortical as well as subcortical regions implicated in psychosis, and considers possible mechanisms whereby cannabis-induced dopamine dysregulation may give rise to delusions and hallucinations. It is concluded that further study of the mechanisms underlying the link between cannabis and psychosis may be conducted productively from the perspective of progressive developmental sensitization, resulting from gene-environment interactions (AU)


Assuntos
Humanos , Psicoses Induzidas por Substâncias/tratamento farmacológico , Dopamina/uso terapêutico , Cannabis/efeitos adversos , Dronabinol/efeitos adversos , Endocanabinoides/farmacocinética , Receptores de Canabinoides
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA